VCNX (Vaccinex) 5-Year EBITDA Growth Rate: 0.00% (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VCNX Vaccinex Inc VCNX
50 GF Score
Price $1.18
View Full Analysis

What is Vaccinex 5-Year EBITDA Growth Rate?

Vaccinex VCNX 50 5-Year EBITDA Growth Rate is 0.00% as of Dec. 2024. GuruFocus rates VCNX with a GF Score™ of 50/100.

Vaccinex's EBITDA per Share for the three months ended in Dec. 2024 was $-1.25.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Vaccinex  (OTCPK:VCNX) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Vaccinex 5-Year EBITDA Growth Rate Related Terms

VCNX vs SXTP, PHGE, CPMV: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Vaccinex's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vaccinex 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaccinex's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Vaccinex's 5-Year EBITDA Growth Rate falls into.


VCNX
50GF Score
Vaccinex Inc VCNX
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaccinex 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
Vaccinex (VCNX) has a 5-Year EBITDA Growth Rate of 0.00% as of Dec. 2024. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Vaccinex and its competitors.
Is Vaccinex's 5-Year EBITDA Growth Rate too high?
Vaccinex's current 5-Year EBITDA Growth Rate is 0.00%. Overall, Vaccinex has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Vaccinex's 5-Year EBITDA Growth Rate compare to SXTP and PHGE?
Vaccinex's 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Vaccinex and its competitors. Vaccinex's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaccinex stock overvalued right now?
Vaccinex (VCNX) has a current 5-Year EBITDA Growth Rate of 0.00%. The current 5-Year EBITDA Growth Rate is 0.00%. Vaccinex's overall GF Score™ is 50/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Vaccinex (VCNX), the current 5-Year EBITDA Growth Rate is 0.00% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vaccinex Business Description

Address 1895 Mount Hope Avenue, Rochester, NY, USA, 14620
Vaccinex Inc is a clinical stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company operates and manages its business as one operating and reportable segment, which is the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company's drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. The firm has also developed a proprietary drug discovery platform, ActivMAb.
50GF Score

Get the complete analysis for VCNX

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.18
Price